Fennec Pharmaceuticals Inc (NASDAQ:FENC - Get Free Report) CEO Rosty Raykov sold 2,431 shares of Fennec Pharmaceuticals stock in a transaction on Tuesday, July 2nd. The shares were sold at an average price of $6.13, for a total value of $14,902.03. Following the completion of the transaction, the chief executive officer now owns 187,471 shares in the company, valued at $1,149,197.23. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
Rosty Raykov also recently made the following trade(s):
- On Monday, June 3rd, Rosty Raykov sold 2,431 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $6.76, for a total value of $16,433.56.
- On Wednesday, May 1st, Rosty Raykov sold 2,431 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $9.11, for a total value of $22,146.41.
- On Friday, April 5th, Rosty Raykov sold 44,300 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $10.75, for a total value of $476,225.00.
- On Wednesday, April 3rd, Rosty Raykov sold 40,584 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $10.78, for a total value of $437,495.52.
Fennec Pharmaceuticals Stock Performance
Shares of FENC opened at $6.03 on Wednesday. The stock has a 50-day moving average of $7.46 and a two-hundred day moving average of $9.24. Fennec Pharmaceuticals Inc has a one year low of $5.99 and a one year high of $11.92. The company has a debt-to-equity ratio of 9.86, a quick ratio of 6.72 and a current ratio of 6.93. The stock has a market cap of $164.74 million, a P/E ratio of 201.00 and a beta of 0.29.
50-year Wall Street Legend Issues July Stock Warning
From Chaikin Analytics | Ad
July is historically the best month of the year for U.S. stocks.
So why are everyone’s favorite tech stocks – including NVDA – stumbling?
To see this July stock warning for yourself – 100% free – click here.
Fennec Pharmaceuticals (NASDAQ:FENC - Get Free Report) last issued its quarterly earnings results on Tuesday, May 14th. The company reported $0.41 EPS for the quarter, missing analysts' consensus estimates of $0.49 by ($0.08). Fennec Pharmaceuticals had a negative return on equity of 39.41% and a net margin of 6.33%. The firm had revenue of $25.38 million for the quarter, compared to analyst estimates of $10.46 million. During the same period in the prior year, the firm posted ($0.23) EPS. As a group, research analysts predict that Fennec Pharmaceuticals Inc will post 0.36 EPS for the current year.
Wall Street Analysts Forecast Growth
FENC has been the topic of several research analyst reports. HC Wainwright dropped their target price on Fennec Pharmaceuticals from $18.00 to $15.00 and set a "buy" rating on the stock in a research note on Wednesday, May 15th. Craig Hallum dropped their target price on Fennec Pharmaceuticals from $20.00 to $17.00 and set a "buy" rating on the stock in a research note on Wednesday, May 15th. Finally, Wedbush reaffirmed an "outperform" rating and set a $16.00 price target on shares of Fennec Pharmaceuticals in a research report on Tuesday, May 14th.
Read Our Latest Report on Fennec Pharmaceuticals
Hedge Funds Weigh In On Fennec Pharmaceuticals
Institutional investors and hedge funds have recently modified their holdings of the stock. Tower Research Capital LLC TRC lifted its holdings in shares of Fennec Pharmaceuticals by 107.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,048 shares of the company's stock valued at $34,000 after buying an additional 1,578 shares during the period. Jump Financial LLC acquired a new position in shares of Fennec Pharmaceuticals in the 4th quarter valued at about $158,000. BNP Paribas Financial Markets lifted its holdings in shares of Fennec Pharmaceuticals by 67.7% in the 1st quarter. BNP Paribas Financial Markets now owns 32,769 shares of the company's stock valued at $364,000 after buying an additional 13,223 shares during the period. Eudaimonia Advisors LLC lifted its holdings in shares of Fennec Pharmaceuticals by 90.8% in the 4th quarter. Eudaimonia Advisors LLC now owns 32,686 shares of the company's stock valued at $367,000 after buying an additional 15,556 shares during the period. Finally, Russell Investments Group Ltd. lifted its holdings in shares of Fennec Pharmaceuticals by 71,275.0% in the 1st quarter. Russell Investments Group Ltd. now owns 34,260 shares of the company's stock valued at $381,000 after buying an additional 34,212 shares during the period. Institutional investors and hedge funds own 55.51% of the company's stock.
Fennec Pharmaceuticals Company Profile
(
Get Free Report)
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
